HK Stock Market Move | KINTOR PHARMA-B (09939) opened high and then dropped, falling more than 21% at one point. Prior to this, the stock price had risen by more than 70% in the past half month.

KINTOR PHARMA-B(09939) opened high this morning, rising nearly 10% before falling, dropping more than 21% at one point during trading. Prior to this, the stock price had risen by over 70% in the past half month. As of the time of writing, it has fallen by 18.38%, to 3.42 Hong Kong dollars, with a trading volume of 42.969 million Hong Kong dollars. On the news front, on the evening of March 18th, Kai Tak Pharmaceutical announced that its independently developed and potentially first-of-its-kind KX-826 Solution 1.0% for the treatment of hair loss had achieved top-line data in the key Phase III clinical trial stage. The data shows that this Phase III stage has met its primary research endpoints, with statistically significant and clinically meaningful results, and both efficacy and safety have shown outstanding performance. This key clinical trial is a multicenter, randomized, double-blind, placebo-controlled adaptive design study in Phase II/III, evaluating the efficacy and safety of KX-826 Solution 1.0% and 0.5% for the topical treatment of Chinese adult male AGA patients. Based on the results of previous clinical trials, the company plans to soon begin communication with Chinese regulatory authorities to submit an application for marketing approval for KX-826 Solution 1.0%. Of note, the official public account of Bayerdorf Group issued a statement last night regarding the maintenance of the innovative achievements and fair competitive environment of Tiannamingduo 630. It mentioned that the company has noticed recent claims and market activities by Suzhou Kai Tak Pharmaceutical Co., Ltd. around KT-939. Bayerdorf has been closely monitoring this for some time and has previously organized a professional team to conduct scientific evaluations, evidence consolidation, and legal arguments, with the related work now in its final stages. The company stated that its previous silence on the matter does not imply endorsement or support for any related statements. Choosing restraint is a sign of respect for science and law, rather than an acknowledgment or concession to the statements made.